Hosted on MSN
ImmunityBio explodes to near 52-week high as bladder cancer drug Anktiva drives massive 700% revenue growth
ImmunityBio Inc. IBRX shares are up on Monday following the company’s announcement of significant revenue growth. • ImmunityBio stock is challenging resistance. Why are IBRX shares at highs? The stock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results